Safety & Performance Study of Verruca Treatment Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

This is a non comparative pre-CE marking pilot clinical investigation is required to evaluate the safety and performance in intended use of the Verruca treatment - NPD396, Class IIa medical device for verrucas in the adult population. The treatment regime will be topical application of the Verruca treatment to the verruca, identified as the reference, once daily for 4 weeks.

Patient & investigator derived outcomes will also be collected to assess clinical performance and adverse events and adverse device effects will be reported to assess safety profile.

Patient assessments will take place pre-treatment to determine patient demography, baseline clinical status, pain and verruca size prior to treatment. Compliance with treatment schedule will be collected via patient diary cards. Furthermore, patients will be assessed on day 2 after starting treatment and then again at 7, 14, 21 & 28 days after starting treatment. Diary cards will completed through-out the investigation.

Patient's assessment of presence or absence of the verruca and associated pain during follow-up period using VAS within diary cards. A set of Patient perception questions will also be included in the diary card.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Male or female patients aged >18 years

Patients with verrucas

Patients should be willing to take part, able to understand the information given to them and give written consent

Exclusion Criteria:

Patient with more than two areas affected by verrucas on one foot

Patient who are actively treating or have treated their wart within the past 8 weeks

Patient suspected to be immunocompromised or are taking immunosuppressants

Patient who suffer from impaired feeling due to diabetes, peripheral vascular disease or neuropathy.

Current participation in another clinical investigation or participation within the last 30 days.

Patient with known sensitivity/allergies to the test materials or any of their ingredients.

Significant current or past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease, which, in the opinion of the Investigator, would compromise the safety of the volunteer or affect the outcome of the investigation (as determined from self-reported medical history questionnaire).

Patient in a situation which in the view of the investigator could interfere with optimal participation in the investigation or constitute a special risk for these patients.

Patient who scar easily or are prone to hypertrophic or Keloid scarring.

Patient who have previously had an unfavourable reaction to any products for the feet and which involved swelling of the foot, or a requirement for painkillers or antibiotics.

Pregnant and lactating females, or those actively seeking to become pregnant in the next month